A phase 1b, open-label, safety, pharmacokinetic, and pharmacodynamic study of an anti-super-enhancer triptolide analogue with nab-paclitaxel plus gemcitabine in patients with metastatic adenocarcinoma of the pancreas.

被引：0
|
作者：
Park, Joon Oh
Hong, Jung Yong
Kim, Seung Tae
Park, Young Suk
Saluja, Ashok
机构：
[1] Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea
[2] Univ Miami, Dept Surg, Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS769
引用
收藏
页码：TPS769 / TPS769
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
    Ruihua Xu
    Xianjun Yu
    Jihui Hao
    Liwei Wang
    Hongming Pan
    Guohong Han
    Jianming Xu
    Yanqiao Zhang
    Shujun Yang
    Jia Chen
    Jieer Ying
    Guanghai Dai
    Mingyu Li
    Damir Begic
    Brian Lu
    Lin Shen
    BMC Cancer, 17
  • [2] Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
    Xu, Ruihua
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jianming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian
    Shen, Lin
    BMC CANCER, 2017, 17
  • [3] Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
    Bekaii-Saab, Tanios
    Okusaka, Takuji
    Goldstein, David
    Oh, Do-Youn
    Ueno, Makoto
    Ioka, Tatsuya
    Fang, Weijia
    Anderson, Eric C.
    Noel, Marcus S.
    Reni, Michele
    Choi, Hye Jin
    Goldberg, Jonathan S.
    Oh, Sang Cheul
    Li, Chung-Pin
    Tabernero, Josep
    Li, Jian
    Foos, Emma
    Oh, Cindy
    Van Cutsem, Eric
    ECLINICALMEDICINE, 2023, 58
  • [4] Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
    Grierson, Patrick M.
    Tan, Benjamin
    Pedersen, Katrina S.
    Park, Haeseong
    Suresh, Rama
    Amin, Manik A.
    Trikalinos, Nikolaos A.
    Knoerzer, Deborah
    Kreider, Brent
    Reddy, Anupama
    Liu, Jingxia
    Der, Channing J.
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    ONCOLOGIST, 2023, 28 (02): : E115 - E123
  • [5] Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Moore, Malcolm J.
    Seay, Thomas E.
    Tjulandin, Sergei
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Van Cutsem, Eric
    Goldstein, David
    Wei, Xinyu
    Iglesias, Jose Luis
    Renschler, Markus Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
    Hidalgo, Manuel
    Garcia-Carbonero, Rocio
    Lim, Kian-Huat
    Messersmith, Wells A.
    Garrido-Laguna, Ignacio
    Borazanci, Erkut
    Lowy, Andrew M.
    Rodriguez, Laura Medina
    Laheru, Daniel
    Salvador-Barbero, Beatriz
    Malumbres, Marcos
    Shields, David J.
    Grossman, Joseph E.
    Huang, Xin
    Tammaro, Meggan
    Martini, Jean-Francois
    Yu, Yanke
    Kern, Kenneth
    Macarulla, Teresa
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (11): : 1326 - 1333
  • [7] Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study
    Yu, X.
    Shen, L.
    Hao, J.
    Wang, L.
    Pan, H.
    Han, G.
    Xu, J.
    Zhang, Y.
    Yang, S.
    Ying, J.
    Li, M.
    Begic, D.
    Lu, B.
    Xu, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 66 - 67
  • [8] Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
    Wainberg, Zev A.
    Hochster, Howard S.
    Kim, Edward J.
    George, Ben
    Kaylan, Aparna
    Chiorean, E. Gabriela
    Waterhouse, David M.
    Guiterrez, Martin
    Parikh, Aparna
    Jain, Rishi
    Carrizosa, Daniel Ricardo
    Soliman, Hatem H.
    Lila, Thomas
    Reiss, David J.
    Pierce, Daniel W.
    Bhore, Rafia
    Banerjee, Sibabrata
    Lyons, Larry
    Louis, Chrystal U.
    Ong, Teng Jin
    O'Dwyer, Peter J.
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4814 - 4822
  • [9] Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial
    Dorman, Klara
    Boeck, Stefan
    Caca, Karel
    Reichert, Maximilian
    Ettrich, Thomas J.
    Oettle, Helmut
    Waidmann, Oliver
    Modest, Dominik P.
    Mueller, Lothar
    Michl, Patrick
    Kanzler, Stephan
    Pink, Daniel
    Reinacher-Schick, Anke
    Geissler, Michael
    Pelz, Henning
    Kunzmann, Volker
    Held, Swantje
    Schichtl, Thomas
    Heinemann, Volker
    Kullmann, Frank
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (10): : 935 - 943
  • [10] Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
    Philip, Philip A.
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto
    Pazo-Cid, Roberto
    Manzano Mozo, Jose L.
    Kim, Edward J.
    Dowden, Scot
    Zakari, Ahmed
    Borg, Christophe
    Terrebonne, Eric
    Rivera, Fernando
    Sastre, Javier
    Bathini, Venu
    Lopez-Trabada, Daniel
    Asselah, Jamil
    Saif, Muhammad Wasif
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thomas
    Hammel, Pascal
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (03): : 285 - 294
12345